[{"from": "human", "value": "Describe this molecule. [C][C][Branch1][C][C][Branch1][C][C][C@@H1][Branch2][=Branch1][Ring2][C][=Branch1][C][=O][N][C][C@@H1][Branch2][Ring2][Ring2][C][C@H1][Ring1][Branch1][C][=Branch1][C][=O][N][C@@][Branch1][#Branch1][C][C@H1][Ring1][Ring1][C][=C][C][=Branch1][C][=O][N][S][=Branch1][C][=O][=Branch1][C][=O][C][C][C][Ring1][Ring1][O][C][=N][C][=C][Branch1][=C][C][=C][Ring1][=Branch1][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][Cl][O][C][N][C][=Branch1][C][=O][O][C][Branch1][C][C][Branch1][C][C][C]"}, {"from": "gpt", "value": "The molecule is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017."}]